GRIN Therapeutics and Angelini Pharma Enter into Exclusive Collaboration to Develop and Commercialize Radiprodil Outside North America
Summary
"We are very pleased to close this financing round and to welcome Angelini Pharmaan ideal partner whose engagement reflects the significant value weve built around the radiprodil program in a relatively short period," said Bruce Leuchter, MD, President & CEO of Neurvati Neurosciences and GRIN Therapeutics. "This strategic collaboration marks an important point of validation for GRIN Therapeutics, the clinical data generated to date, and the potential of radiprodil as the first approved treatment for patients with GRIN-related neurodevelopmental disorder (GRIN-NDD)a population with urgent unmet need. ""Angelini Pharma is a leading international pharmaceutical company and we are thrilled to have their backing, partnership and commitment to the further growth of GRIN Therapeutics and development of radiprodil," said Kiran Reddy, MD, Senior Managing Director, Blackstone Life Sciences. "The teams rapid progress with radiprodilachieving multiple regulatory designations and advancing toward a pivotal Phase 3 trial is very promising and todays milestone also validates the ability of Neurvatis model to efficiently develop high-impact neuroscience therapies. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients lives and currently has more than $12 billion in assets under management.